From January 1, 2024 to March 31, 2024, the company has repurchased 11,804,907 shares, representing 1.45% for CNY 222.56 million. With this, the company has completed the repurchase of 17,763,061 shares, representing 2.2% for CNY 345.45 million under the buyback announced on July 17, 2023.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
27.87 CNY | +0.94% | -2.35% | +25.37% |
May. 24 | Jafron Biomedical Co.,Ltd. Announces Final Dividend on A Shares for 2023, Payable on 31 May 2024 | CI |
Apr. 26 | Jafron Biomedical Co.,Ltd. Proposes Final Dividend for the Year 2023 | CI |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+25.37% | 2.98B | |
-8.49% | 175B | |
-1.93% | 107B | |
-7.57% | 65.05B | |
+2.69% | 50.76B | |
+6.89% | 43.14B | |
+5.93% | 41.46B | |
+14.70% | 30.69B | |
+13.37% | 25.39B | |
-4.93% | 23.69B |
- Stock Market
- Equities
- 300529 Stock
- News Jafron Biomedical Co.,Ltd.
- Tranche Update on Jafron Biomedical Co.,Ltd.'s Equity Buyback Plan announced on July 17, 2023.